Robin Y Smith Founder and CEO of ORIG3N is a visionary and strategist with a proven track record of successfully building high-energy software organizations. ORIG3N is a biotechnology company developing a breakthrough disease-modeling platform targeting rare genetically inherited diseases. By advancing screening projects using iPSC-derived differentiated cells and rapidly delivering the resulting data to inform therapeutic decisions, ORIG3N will replace trial and error guess work of treating disease and enable longer, healthier lives. For more information, visit: www.orig3n.com.

Robin is passionate about building startup organizations and entrepreneurship.

In 2007 Mr. Smith founded ArtusLabs, Inc. ArtusLabs was acquired in 2011 by PerkinElmer (NYSE: PKI) as a key component of the scientific informatics focus that is infused with rich chemical and biological conventions that conform to the special “language” and needs of scientists. Prior to ArtusLabs, Mr. Smith was the Founder and CEO of Synthematix. He established Synthematix as a leader in the electronic lab notebook market and led the organization through its acquisition by Symyx Technologies.

Smith’s earlier experiences include a 10-year career in synthetic chemistry, @Burroughs Wellcome Co. (Glaxo-SmithKline), material science synthesis @Lord Corporation and biotech experiences @Boron Biologicals where many of the novel Boron Neutron Capture Therapy (BNCT) reagents invented were utilized in clinical trials for glioblastomal cancer. He later founded RYSCOR Science (acquired by Synthonix), a synthetic chemistry outsourcing company before moving into the life science technology space.

Robin is a life-long student of creative entrepreneurship. His interests include developing creative and productive startup teams, developing technologies that can transform industries and bettering the human condition through technology. Robin holds six US patents. Robin is also a certified scuba dive master and has cataloged over 1000 explorations.